List view / Grid view

Articles

Filter the results

 

COVID-19 therapies in the pipeline

15 September 2020 | By

As the global COVID-19 situation is rapidly changing, staying abreast with the latest news can be challenging. In this article, Sheraz Gul provides an overview of the broad range of potential treatments in development and discusses how the regulatory landscape can shift at any time.

Novel biomarker technology for cancer diagnostics

11 September 2020 | By

A new way of identifying cancer biomarkers has been developed by researchers at Lund University in Sweden. The new technology allows very sensitive, quick and cost-effective identification of cancer biomarkers. Nikki Withers spoke to Professor Carl Borrebaeck, who discusses how the researchers demonstrated the power of combining proteomics with genomics.

Under the microscope: Transforming drug discovery on membrane proteins

11 September 2020 | By

IN NOVEMBER 2017, leadXpro chose to strengthen its capabilities with the Creoptix™ WAVEsystem. “We were looking for a label‑free, biophysical method to investigate binding affinity and kinetics of small molecules with challenging integral membrane proteins,” explained Michael Hennig, Chief Executive Officer of leadXpro.

Under the microscope: Supporting the COVID-19 response with NGS

11 September 2020 | By

Responding efficiently to urgent situations is of utmost importance in times of crisis. Dr Suvarna Gandlur, Associate Director of Takara Bio’s next-generation sequencing (NGS) portfolio, discusses how the company is contributing to the COVID-19 effort and supporting the scientific community.

Advancing cell therapies with engineered Tregs

10 September 2020 | By

Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, such as Crohn’s disease and multiple sclerosis, as…